Tickers
Ipsen (Euronext: IPN; ADR: IPSEY) reported late-breaking Phase III ELSPIRE data showing IQIRVO achieved alkaline phosphatase (ALP) normalization in 85.3% of patients at week 52 versus 23.3% on placebo in primary biliary cholangitis (PBC), with generally good tolerability. The results, to be presented at The Liver Meeting 2026 and published simultaneously in HEPATOLOGY, support ALP normalization as an achievable treatment goal in PBC.
Ipsen (Euronext: IPN; ADR: IPSEY) announced late-breaking data from the Phase III ELSPIRE study in people living with primary biliary cholangitis (PBC) whose alkaline phosphatase (ALP) levels are between 1 and 1.67× the upper limit of normal (ULN).
Key efficacy results
At week 52, 85.3% of patients receiving IQIRVO achieved ALP normalization, compared with 23.3% on placebo, according to the announcement. The company described tolerability as generally good.
Presentation and publication
The ELSPIRE results will be presented as late-breaking data at The Liver Meeting 2026 and published simultaneously in HEPATOLOGY, the flagship journal of the AASLD.
Treatment goal
According to Ipsen, these results reinforce the growing body of data indicating that ALP normalization is an achievable treatment goal in PBC.
At a glance
- Study: Phase III ELSPIRE
- Population: People with PBC and ALP levels between 1 and 1.67× ULN
- Primary reported outcome: ALP normalization at week 52
- Results: 85.3% with IQIRVO vs. 23.3% with placebo
- Tolerability: Generally good
- Disclosure: Late-breaking presentation at The Liver Meeting 2026; simultaneous publication in HEPATOLOGY
The announcement was dated November 5, 2026, and issued from Paris, France.